secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-149424
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics announces 2023 annual meeting voting results
---------------------------------------------------------------

- Simon Tate elected as Class II director with 21,144,596 votes for, 555,897 withheld, 891,450 broker non-votes.
- Ratification of PricewaterhouseCoopers as auditor: 22,574,271 for, 3,897 against, 13,775 abstentions.
- Annual meeting held virtually on May 18, 2023; two proposals voted on.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312523149424/0001193125-23-149424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312523149424/d501370d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-149424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer